Chugai Of Japan Bets Future On Cancer Drugs, Not Tamiflu
This article was originally published in PharmAsia News
Executive Summary
Japan's Chugai Pharmaceutical is basing its long-term business not on its huge-selling Tamiflu (oseltamivir) flu drug, but on cancer drugs